PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: PIPELINE PART 07: MARKET SEGMENTATION BY TYPE Market segmentation by type Comparison by type Biologics - Market size and forecast 2018-2023 Small molecules - Market size and forecast 2018-2023 Market opportunity by type PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES Market drivers Market challenges PART 12: MARKET TRENDS PART 13: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 14: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Bristol-Myers Squibb Co. Eli Lilly and Co. F. Hoffmann-La Roche Ltd. Merck & Co. Inc. Sanofi PART 15: APPENDIX Research methodology List of abbreviations Definition of vendors classification PART 16: EXPLORE TECHNAVIO   Exhibit 01: Global oncology therapeutics market Exhibit 02: Segments of global oncology therapeutics market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Global laryngeal cancer therapeutics market pipeline: Overview Exhibit 18: Global laryngeal cancer therapeutics market pipeline: Snapshot Exhibit 19: Type - Market share 2018-2023 (%) Exhibit 20: Comparison by type Exhibit 21: Biologics - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Biologics - Year-over-year growth 2019-2023 (%) Exhibit 23: Small molecules - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Popular chemotherapies for treatment of laryngeal cancer Exhibit 25: Small molecules - Year-over-year growth 2019-2023 (%) Exhibit 26: Market opportunity by type Exhibit 27: Customer landscape Exhibit 28: Market share by geography 2018-2023 (%) Exhibit 29: Geographic comparison Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 31: North America - Year-over-year growth 2019-2023 (%) Exhibit 32: Top 3 countries in North America Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Europe - Year-over-year growth 2019-2023 (%) Exhibit 35: Top 3 countries in Europe Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 37: Asia - Year-over-year growth 2019-2023 (%) Exhibit 38: Top 3 countries in Asia Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 40: ROW - Year-over-year growth 2019-2023 (%) Exhibit 41: Top 3 countries in ROW Exhibit 42: Key leading countries Exhibit 43: Market opportunity Exhibit 44: Impact of drivers and challenges Exhibit 45: Vendor landscape Exhibit 46: Landscape disruption Exhibit 47: Vendors covered Exhibit 48: Vendor classification Exhibit 49: Market positioning of vendors Exhibit 50: Bristol-Myers Squibb Co. - Vendor overview Exhibit 51: Bristol-Myers Squibb Co. - Product segments Exhibit 52: Bristol-Myers Squibb Co. - Organizational developments Exhibit 53: Bristol-Myers Squibb Co. - Geographic focus Exhibit 54: Bristol-Myers Squibb Co. - Key offerings Exhibit 55: Bristol-Myers Squibb Co. - Key customers Exhibit 56: Eli Lilly and Co. - Vendor overview Exhibit 57: Eli Lilly and Co. - Business segments Exhibit 58: Eli Lilly and Co. - Organizational developments Exhibit 59: Eli Lilly and Co. - Geographic focus Exhibit 60: Eli Lilly and Co. - Segment focus Exhibit 61: Eli Lilly and Co. - Key offerings Exhibit 62: Eli Lilly and Co. - Key customers Exhibit 63: F. Hoffmann-La Roche Ltd. - Vendor overview Exhibit 64: F. Hoffmann-La Roche Ltd. - Business segments Exhibit 65: F. Hoffmann-La Roche Ltd. - Organizational developments Exhibit 66: F. Hoffmann-La Roche Ltd. - Geographic focus Exhibit 67: F. Hoffmann-La Roche Ltd. - Segment focus Exhibit 68: F. Hoffmann-La Roche Ltd. - Key offerings Exhibit 69: F. Hoffmann-La Roche Ltd. - Key customers Exhibit 70: Merck & Co. Inc. - Vendor overview Exhibit 71: Merck & Co. Inc. - Business segments Exhibit 72: Merck & Co. Inc. - Organizational developments Exhibit 73: Merck & Co. Inc. - Geographic focus Exhibit 74: Merck & Co. Inc. - Segment focus Exhibit 75: Merck & Co. Inc. - Key offerings Exhibit 76: Merck & Co. Inc. - Key customers Exhibit 77: Sanofi - Vendor overview Exhibit 78: Sanofi - Business segments Exhibit 79: Sanofi - Organizational developments Exhibit 80: Sanofi - Geographic focus Exhibit 81: Sanofi - Segment focus Exhibit 82: Sanofi - Key offerings Exhibit 83: Sanofi - Key customers Exhibit 84: Validation techniques employed for market sizing Exhibit 85: Definition of vendors classification

Bristol-Myers Squibb Co. Eli Lilly and Co. F. Hoffmann-La Roche Ltd. Merck & Co. Inc. Sanofi